1. Home
  2. BDSX vs MAIA Comparison

BDSX vs MAIA Comparison

Compare BDSX & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$7.95

Market Cap

53.0M

Sector

Health Care

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.37

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
MAIA
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.0M
44.9M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
BDSX
MAIA
Price
$7.95
$1.37
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.50
N/A
AVG Volume (30 Days)
63.1K
873.7K
Earning Date
11-03-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$80,173,000.00
N/A
Revenue This Year
$20.75
N/A
Revenue Next Year
$25.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.29
N/A
52 Week Low
$3.44
$0.87
52 Week High
$32.20
$2.74

Technical Indicators

Market Signals
Indicator
BDSX
MAIA
Relative Strength Index (RSI) 52.12 56.22
Support Level $7.77 $1.07
Resistance Level $8.38 $1.25
Average True Range (ATR) 0.57 0.16
MACD -0.01 0.06
Stochastic Oscillator 60.38 54.41

Price Performance

Historical Comparison
BDSX
MAIA

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: